HUTCHMED (China) Ltd (HCM) Form 6-K — Oct 27, 2026
HUTCHMED announced it will host an expert webcast on November 5, 2026, co-hosted with Citigroup, to discuss recent Phase III savolitinib data in MET-driven non-small cell lung cancer presented at the ESMO Congress 2026. The event will feature Professor Yi-Long Wu, principal investigator of the SANOVO study in China, alongside HUTCHMED CEO (on leave) and CSO Dr Weiguo Su, covering both the SANOVO trial and the global SAFFRON study. The SAFFRON Phase III trial reported positive high-level results in August 2026, showing statistically significant and clinically meaningful improvement in progression-free and overall survival for savolitinib plus TAGRISSO versus chemotherapy.
Key figures
- Webcast date
- 2026-11-05
- Saffron centers
- 230
- Sanovo patients
- 326
- Saffron patients
- 338
- Saffron countries
- 29
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.